Health Care Systems
Health care systems organise the finance and delivery of health care. They vary by country, reflecting specific history, culture, and economics. To maximise coverage and efficiency they must evolve with changing demographics, needs, and technologies.
Why President Trump’s generic drug tariffs are unlikely to fix America’s supply problem
13 August 2026
America’s dependence on foreign generic manufacturing is a real national security and supply concern. The vast majority of drug shortages in the U.S. are generics and shortages have increasingly burdened pharmacies across the country and disrupted care for the patients who rely on them, particularly those with chronic pain and cancer.
But President Trump’s most recent policy is unlikely to fix that problem. It’s far more likely to make American medicine cabinets less reliable, not more.
What the first EU JCA reveals about assessing precision oncology
28 July 2026
We explore how the first JCA provides insights into the longstanding methodological challenge of evidence generation and comparative assessment for precision medicine.
Net zero healthcare: Does HTA have a role to play?
7 July 2026
As part of those efforts, should environmental impacts be taken into consideration when assessing the value of new health technologies? Grace Hampson is joined by Koonal Shah, Associate Director and Head of Science Policy at NICE, and Chris Sampson,…
Around the world in HTAs: Abu Dhabi – Advancing HTA and value-based healthcare in the UAE
1 July 2026
Abu Dhabi is taking important steps to strengthen the use of HTA in healthcare decision-making, with the publication of its HTA guidelines in 2025 marking an important milestone.
Can HTA keep up with innovation?
23 June 2026
But the pace of innovation often outruns policy – new developments in innovative therapies, digital health technologies, and a shifting geopolitical landscape are pushing HTA systems…
Cost-effectiveness thresholds: theory, pragmatism, and NICE’s new number
16 June 2026
Grace Hampson is joined by Adrian Towse, who ran OHE as its Director for many years, and Chris Sampson, Senior Principal Economist at OHE, to dig into one…
Most Favored Nation pricing: what it means for policy, patients and pharma
5 May 2026
US pharmaceutical prices are the highest in the world – President Trump’s Most Favoured Nation (MFN) policy is trying to change that. But what does MFN pricing mean in practice?
The value of fast diagnostics in time-critical infections
20 April 2026
Advancing earlier intervention in time‑critical infections Sepsis continues to impose a substantial global burden, with millions of cases and high mortality each year. Patients with bloodstream…
The burden of LDL-cholesterol-driven atherosclerotic cardiovascular diseases
31 March 2026
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality globally, and is responsible for substantial health and economic burden to health systems and wider society.